Milnacipran s Tolerance and Safety
{"Image DocumentName": "Milnacipran s Tolerance and Safety", "Image ImageDescription": "Sleep. A significant improvement of objective sleep parameters. \uf0a7 associated with the clinical improvement of depression. Polysomnographic results. Baseline. Days 4-6. Days Total sleep time (min)   Stage I sleep (min) (% of total sleep) 44 (13.3%) 44 (11.7%) 49 (12.2%) Stage II sleep (min) (% of total sleep) 190 (57.4%) 240   (64.0%) 243  (60.3%) Stage III and IV(slow wave) sleep (min) (% of total sleep) 27 (8.2%) 33 (8.8%) 42 (10.4%) REM sleep (min) (% of total sleep) 70 (21.2%) 58 (15.5%  ) 69 (17.1% ) REM latency (min)    80   Mean REM episode duration (min) Sleep efficiency index   84.5  Sleep latency (min) 24   27. Intrasleep awake time (min/h) Number of awakenings(a) per hour The clinical improvement of depression during treatment with IXEL\uf0d2 is accompanied by a significant improvement of objective sleep parameters, such as : \uf0ca an improvement of the total duration of sleep (principally due to a major increase in stage II sleep significant from D4-6), \uf0ca a significant reduction, within 4-6 days, of the sleep latency, \uf0ca a significant increase in sleep efficiency as soon as D4-6.  p<0.05;   p<0.01 vs baseline (Student\u2019s t-test); (a) at least 1 minute in \u2018awake\u2019 sleep stage. Lemoine P, Faivre Th. Subjective and polysomnographic effects of milnacipran on sleep in depressed patients. Hum Psychopharmacl Clin Exp 2004;19:", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}